Blanver wants to expand area of medicines

The Brazilian pharmaceutical market is heated. With annual growth by turning around 20%, the idea to manufacture medicines has attracted more and more people. In the case of the Blanver industry, specialized in manufacturing of excipients — the drug not part of a medicine (see text below). From 2011, the company has invested in the manufacturing of medicines to the Government. For now, the portfolio is composed of only one item, but must receive a new product still in January and two other drugs are in the final stages of research. "This year, the production of drugs must have a highlight for our company," he said, to BRASIL ECONOMICO, Sérgio Frangioni, President of Blanver.
In 2013, Blanver expects to earn r $ 250 million, 20 percent more value to that achieved last year. "That Bill or we are including the possible gains with drugs that are not yet at the stage of registration, but it is possible that they come on the market in 2013," said Frangioni. According to him, if the records come out quickly, the impact in sales can be great.
Even before starting the production of their own medicines, Blanver already had a line for the production of drugs. Since 1996 the company outsources the production of several national and multinational pharmaceutical industries. "In some cases, we are the only ones responsible for the manufacture of any product", says the Executive. For this year, he plans to double the production capacity of this business area. For this, the company prepares investments in new equipment and hiring more employees.
In parallel to progress in the business of drug production, Frangioni cannot neglect of the area that gave birth to the company, the production of excipients. For 2012, the segment received an investment of $ 10 million to increase production at 20%. "We were at the limit of the ability and the conquest of new markets, such as India and China, us to expand." New investments are already planned for the area. "Haven't we close the values, but we must apply a few more tens of millions over the next three years." With this, the company aims to respond by 15% of sales of excipients in the world. Today the company has just over 10% of the market. "Much of the growth in that part of the business will come from abroad, since 70% of all excipients that produce are out of the country," said Frangioni. Even with only 30% of the production for the local market, it is estimated that Blanver has more than 60% of the market share.
New areas
For 2013, Frangioni believes the deal will live a consolidation phase. "We made some investments and we need to let things take shape before taking another step." Despite this, he does not deny that it study new areas of business, which can now start work next year. "We must always keep an eye on that is synergistic. In the case of outsourcing and production of medicines. Already have outsourcing absorbed costs to launch own production. "